查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600013

癌症药物市场：按给药途径、治疗类型、类型和最终用户分类 - 全球预测 2025-2030

Cancer Drugs Market by Route of Administration (Intravenous, Oral, Topical), Type of Therapy (Chemotherapy, Combination Therapy, Hormonal Therapy), Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症治疗市值为1445亿美元，预计到2024年将达到1577.6亿美元，复合年增长率为9.57%，到2030年将达到2740.5亿美元。

癌症药物市场包括旨在治疗各种形式癌症的各种治疗解决方案。这个市场包括化疗、免疫疗法、标靶治疗、荷尔蒙疗法和其他创新疗法。全球癌症发病率上升、医疗技术进步以及对早期检测和治疗方案认识的提高支持了对抗癌药物的需求。这些药物有多种最终用户应用，包括医院、诊所和专门的癌症治疗中心。市场成长的主要影响因素包括製药公司研发投入的增加、精准医疗的重大进展以及新型抗癌药物核准率的提高。人口老化的迅速增加和生活方式的改变进一步推动了对有效癌症治疗的需求。潜在的治疗机会在于个人化医疗的日益采用和生物相似药的日益接受，它们提供了具有成本效益的治疗选择。公司可以透过专注于开发针对个别患者情况的生物相似药和精准医疗来利用这些机会。然而，新兴市场也面临着高昂的药物开发成本、严格的监管要求以及癌症病理生理学的复杂性等限制，这些限制阻碍了创新和市场进入。此外，与癌症治疗相关的副作用对广泛接受提出了挑战。创新和研究将专注于增强药物输送系统、探索联合治疗以及利用人工智慧进行早期诊断和个人化治疗规划，从而为公司提供成长之路，同时改善患者的治疗效果。癌症药物市场竞争激烈，技术进步频繁，策略联盟频繁。成功的公司是那些保持营运灵活性、利用新兴技术并有效驾驭监管环境、及时将有效的新治疗方法推向市场的公司。

主要市场统计
基准年[2023] 1,445亿美元
预测年份 [2024] 1577.6亿美元
预测年份 [2030] 2740.5亿美元
复合年增长率（%） 9.57%

市场动态：揭示快速发展的癌症药物市场的关键市场洞察

供需的动态交互作用正在改变癌症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 癌症疾病增加和认识提高
    • 政府和医疗机构对癌症治疗的支持措施
  • 市场限制因素
    • 抗癌药物研发成本高及产品召回问题
  • 市场机会
    • 基因组和分子研究的进展导致个人化癌症治疗
    • 加大学名药研发投入
  • 市场挑战
    • 与癌症药物相关的严格监管要求

波特五力：驾驭癌症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对癌症药物市场的影响

外部宏观环境因素在塑造癌症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症治疗药物市场的竞争状况

对癌症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症治疗市场供应商的绩效评估

FPNV定位矩阵是评估癌症治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘癌症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，癌症药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症疾病的数量和认识的增加
      • 政府和卫生机构支持癌症治疗的努力
    • 抑制因素
      • 与癌症药物相关的高研发成本和产品召回问题
    • 机会
      • 基因组和分子研究的进步带来个人化癌症治疗
      • 加大学名药研发投入
    • 任务
      • 与癌症药物相关的严格监管要求
  • 市场区隔分析
    • 治疗类型：由于长期缓解且副作用较少，免疫疗法越来越受到青睐
    • 最终用户：个人化健康计画在居家照护中越来越受欢迎
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症药物市场：依给药途径分类

  • 静脉
  • 口服
  • 话题

第七章依治疗类型分類的癌症治疗药物市场

  • 化疗
  • 联合治疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射治疗
  • 标靶治疗

第八章癌症治疗市场：按类型

  • 膀胱癌
  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 食道癌
  • 肾癌
  • 肝癌
  • 肺癌
  • 摄护腺癌
  • 胃癌

第九章癌症药物市场：依最终用户分类

  • 诊所
  • 居家护理
  • 医院

第10章美洲抗癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太癌症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的癌症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Lantern Pharmaceuticals 和 OHSU 合作利用人工智慧开发先进的癌症治疗方法
    • 工业以 24 亿美元收购 Decifera Pharmaceuticals 以加强肿瘤产品组合
    • Zydus Lifesciences 推出新药 Ivira，扩大印度癌症治疗选择
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen MA Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hofmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt PLC
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Group
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market was valued at USD 144.50 billion in 2023, expected to reach USD 157.76 billion in 2024, and is projected to grow at a CAGR of 9.57%, to USD 274.05 billion by 2030.

The cancer drugs market encompasses a diverse range of therapeutic solutions aimed at treating various forms of cancer. This market includes chemotherapy, immunotherapy, targeted therapy, hormone therapy, and other innovative treatments. The necessity of cancer drugs is underscored by the rising prevalence of cancer globally, advancing medical technology, and increasing awareness about early detection and treatment options. These drugs find application across multiple end-users such as hospitals, clinics, and specialized cancer treatment centers. Key influencing factors for market growth include heightened investment in R&D by pharmaceutical companies, significant advancements in precision medicine, and the increasing approval rates of new cancer drugs. The surge in geriatric population and lifestyle changes further expedite the demand for effective cancer treatments. Potential opportunities lie in the rising adoption of personalized medicine and the growing acceptance of biosimilars, which provide cost-effective treatment alternatives. Companies can leverage these opportunities by intensifying their focus on developing biosimilars and precision medicine tailored to individual patient profiles. However, the market also faces limitations such as high costs of drug development, rigorous regulatory requirements, and the complex nature of cancer pathophysiology, which can hamper innovation and market entry. Additionally, side effects associated with cancer treatments pose challenges to widespread acceptance. Innovation and research could pivot towards enhancing drug delivery systems, exploring combination therapies, and leveraging AI for early diagnosis and personalized treatment plans, thereby offering businesses growth avenues while improving patient outcomes. The cancer drugs market is increasingly competitive, characterized by frequent technological advancements and strategic collaborations. Companies that will succeed are those that maintain agility in their operations, capitalize on emerging technologies, and navigate regulatory landscapes effectively to bring new, effective treatments to market in a timely manner.

KEY MARKET STATISTICS
Base Year [2023] USD 144.50 billion
Estimated Year [2024] USD 157.76 billion
Forecast Year [2030] USD 274.05 billion
CAGR (%) 9.57%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Drugs Market

The Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing number and awareness of cancer diseases
    • Governments and health organizations' supportive initiatives for cancer treatment
  • Market Restraints
    • High R&D cost and product recall issues associated with cancer drug
  • Market Opportunities
    • Advancements in genomic and molecular research leading to personalized cancer treatments
    • Increasing investment in generic medicine development
  • Market Challenges
    • Stringent regulatory requirements associated with cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Drugs Market

A detailed market share analysis in the Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Drugs Market

A strategic analysis of the Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen MA Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hofmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Ipsen Pharma, Johnson & Johnson Services, Inc., Mallinckrodt PLC, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Group, Sumitomo Pharma Co., Ltd., Sun Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Type of Therapy, market is studied across Chemotherapy, Combination Therapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
  • Based on Type, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on End-User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing number and awareness of cancer diseases
      • 5.1.1.2. Governments and health organizations' supportive initiatives for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D cost and product recall issues associated with cancer drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic and molecular research leading to personalized cancer treatments
      • 5.1.3.2. Increasing investment in generic medicine development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements associated with cancer drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type of therapy : Increasing preference for immunotherapy due to its long-term remission and reduced side effects
    • 5.2.2. End-user : Rising preference for personalized medicine plans in homecare
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Drugs Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Intravenous
  • 6.3. Oral
  • 6.4. Topical

7. Cancer Drugs Market, by Type of Therapy

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Combination Therapy
  • 7.4. Hormonal Therapy
  • 7.5. Immunotherapy
  • 7.6. Radiation Therapy
  • 7.7. Targeted Therapy

8. Cancer Drugs Market, by Type

  • 8.1. Introduction
  • 8.2. Bladder Cancer
  • 8.3. Breast Cancer
  • 8.4. Cervical Cancer
  • 8.5. Colorectal Cancer
  • 8.6. Esophagus Cancer
  • 8.7. Kidney Cancer
  • 8.8. Liver Cancer
  • 8.9. Lung Cancer
  • 8.10. Prostate Cancer
  • 8.11. Stomach Cancer

9. Cancer Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Homecare
  • 9.4. Hospitals

10. Americas Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Lantern Pharmaceuticals and OHSU Join Forces to Develop Advanced AI-Driven Cancer Treatments
    • 13.3.2. Ono Pharmaceutical Acquires Deciphera Pharmaceuticals in USD 2.4 Billion Deal to Bolster Oncology Portfolio
    • 13.3.3. Zydus Lifesciences Expands Cancer Treatment Options in India with Launch of New Drug Ibyra
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen MA Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. Eli Lilly and Company
  • 11. F. Hofmann-La Roche Ltd.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Incyte Corporation
  • 15. Ipsen Pharma
  • 16. Johnson & Johnson Services, Inc.
  • 17. Mallinckrodt PLC
  • 18. Merck KGaA
  • 19. Novartis AG
  • 20. Pfizer, Inc.
  • 21. Regeneron Pharmaceuticals, Inc.
  • 22. Sanofi Group
  • 23. Sumitomo Pharma Co., Ltd.
  • 24. Sun Pharmaceuticals Limited
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023